Inception Growth Acquisition LTD 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

OTC.Pink
Inception Growth Acquisition Limited reported a significant net loss for Q3 2025 and the nine-month period, while extending its business combination deadline with AgileAlgo Holdings to February 2026 amidst declining trust account funds and a going concern warning.
OTC.Pink
Inception Growth Acquisition Limited reports increased losses and significant redemptions, raising substantial doubt about its ability to continue as a going concern without a timely business combination.
OTC.Pink
Inception Growth Acquisition Limited reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern due to delays in completing a business combination.
OTC.Pink
Inception Growth Acquisition Limited reported its financial results for the quarter ended September 30, 2024, while continuing its efforts to complete a business combination.
OTC.Pink
Inception Growth Acquisition Limited reported a net income of $134,091 for the three months ended June 30, 2024, while continuing efforts to finalize a business combination.
OTC.Pink
Inception Growth Acquisition Limited has filed an amendment to its quarterly report to restate its financial statements due to errors in accounting for deferred underwriting compensation and non-redemption agreement expenses.
OTC.Pink
Inception Growth Acquisition Limited has filed an amendment to its quarterly report to restate its unaudited condensed financial statements for the six months ended June 30, 2023, due to errors in accounting for deferred underwriting compensation and non-redemption agreement expenses.
OTC.Pink
Inception Growth Acquisition Limited has amended its Q1 2023 report to correct errors in deferred underwriting compensation and non-redemption agreement expenses.
OTC.Pink
Inception Growth Acquisition Limited has amended its quarterly report to correct an overstatement of deferred underwriting compensation, leading to a restatement of financial statements.
OTC.Pink
Inception Growth Acquisition Limited has amended its quarterly report to restate financial statements due to an overstatement of deferred underwriting compensation.
OTC.Pink
Inception Growth Acquisition Limited has filed an amendment to its Q1 2022 report to correct an overstatement of deferred underwriting compensation.
OTC.Pink
Inception Growth Acquisition Limited reported a net income of $128,029 for the first quarter of 2024, while continuing its efforts to finalize a business combination.